YTENQ has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
YTENQ has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Yield10 Bioscience has the GF Score of 0, which implies that the company might have Worst future performance potential, or not enough data.
The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.
GF Score takes following five key aspects into consideration:
1. Financial Strength : 0/10Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.
Based on research and backtesting result, GuruFocus believes Yield10 Bioscience might have Worst future performance potential, or not enough data.
Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.
Yield10 Bioscience (OTCPK:YTENQ) GF Score Explanation
Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:
GF Score | Performance Potential and All-in-One Screener Examples (1) |
91 - 100 | Highest outperformance potential |
81 - 90 | Good outperformance potential |
71 - 80 | Likely to have average performance |
51 - 70 | Poor future performance potential |
0 - 50 | Worst future performance potential, or not enough data |
(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.
Thank you for viewing the detailed overview of Yield10 Bioscience's GF Score provided by GuruFocus.com. Please click on the following links to see related term pages.
Jack W Schuler | 10 percent owner | 100 N. FIELD DRIVE, SUITE 360, LAKE FOREST IL 60045 |
Richard William Hamilton | director | 1535 RANCHO CONEJO BOULEVARD, THOUSAND OAKS CA 91320 |
Willie Loh | director | C/O YIELD10 BIOSCIENCE, INC., 19 PRESIDENTIAL WAY, WOBURN MA 01801 |
Charles B Haaser | officer: VP Fin and CAO | |
Lynne H Brum | officer: VP Planning and Comms | 21 ERIE STREET, CAMBRIDGE MA 02139 |
Kristi Snell | officer: VP Research & CSO | C/O METABOLIX, INC., 19 PRESIDENTIAL WAY, SUITE 201, WOBURN MA 01801 |
Anthony J Sinskey | director | C/O METABOLIX, 21 ERIE STREET, CAMBRIDGE MA 02139 |
Sherri M. Brown | director | C/O YIELD10 BIOSCIENCE, INC., 19 PRESIDENTIAL WAY, SUITE 201, WOBURN MO 01801 |
Oliver P Peoples | director, officer: Pres & CEO | C/O METABOLIX, INC., 21 ERIE STREET, CAMBRIDGE MA 02139 |
Joseph H Shaulson | director | C/O METABOLIX, INC., 21 ERIE STREET, CAMBRIDGE MA 02139 |
Peter N Kellogg | director | MERCK & CO., INC, ONE MERCK DRIVE., P.O. BOX 100, WHITEHOUSE STATION NJ 08889-0100 |
Celeste Beeks Mastin | director | 21 ERIE STREET, CAMBRIDGE MA 02139 |
Van Nostrand Robert L | director | C/O ACHILLION PHARMACEUTICALS, INC., 300 GEORGE STREET, NEW HAVEN CT 06511 |
Matthew Strobeck | director | C/O METABOLIX, INC., 21 ERIE STREET, CAMBRIDGE MA 02139 |
William P Scully | 10 percent owner | C/O MCGRATH DOYLE & PHAIR, 150 BROADWAY, NEW YORK NY 10038 |
From GuruFocus
By GuruFocus Research • 02-09-2024
By Marketwired • 05-23-2024
By GuruFocus Research • 02-09-2024
By GuruFocus Research • 02-09-2024
By Marketwired • 05-15-2024
By GuruFocus Research • 02-09-2024
By GuruFocus Research • 02-09-2024
By GuruFocus Research • 02-09-2024
By GuruFocus Research • 02-09-2024
By GuruFocus Research • 02-09-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.